Skip to content

Post-market surveillance study on SRS Implant

Post-market surveillance study on SRS Implant - PMCFU SRS Implant

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00016753
Enrollment
150
Registered
2019-08-28
Start date
2018-12-12
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N81

Interventions

Group 1: Questionnaire on application of the SRS Implant. All patients of a clinic treated with the SRS Implant may be included.

Sponsors

pfm medical ag
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
21 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients older than 21 years suffering from symptomatic anterior vaginal and apical Prolapse (POP = stage II).

Exclusion criteria

Exclusion criteria: Exclusion criteria result from the contraindications listed in the manufacturer’s IFU based on their technical documentation. The SRS Implant is contraindicated for use in any patient in whom soft tissue implants are contraindicated. In addition, patients with: • Pathology of the pelvic soft tissue; • Pregnant patients, or patients that are considering future pregnancies; • Any pathology, including known or suspected uterine/cervical/vaginal/bladder pathology, which would compromise placement (e.g. anatomical distortion or abnormalities); • Any pathology that would limit blood supply and compromise healing (e.g. decreased blood supply to organs because of treatments such as radiation therapy, chemotherapy); • Presence of known or suspected cancer of the vagina, cervix, bladder or uterus; • Blood coagulation disorder; • Autoimmune connective tissue disease; • Renal insufficiency and urinary tract obstruction; • Pre-existing local or systemic infection (note: treat the infection with the appropriate antiseptics and/or antibiotics to eliminate the infection before placing the SRS Implant); • And sensitivity/allergy to polypropylene or titanium-dioxide or polyether ether ketone (PEEK). Furthermore, patients with a mesh already implanted are excluded.

Design outcomes

Primary

MeasureTime frame
Usability assessment of the SRS Implant during the implantation

Secondary

MeasureTime frame
Clinical aspects of the device usage: Occurrence of complications (periprocedural); duration of the procedure (with respect to patient safety/satisfaction)

Countries

Germany, Hungary

Contacts

Public ContactAngelika Greser

pfm medical ag

angelika.greser@pfmmedical.com+4922369641251

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026